Following the growth of the orphan drug industry and the increasing appetite of investors, we interviewed Patrick Enright, Managing Director of Menlo Park based venture capital firm Longitude Capital to discuss some of the current challenges in investing in orphan drug companies.
If you want to learn more about:
- What stage of development are investors looking for
- Deals models
- How investors are assessing clinical risk
- Challenges and opportunities of publicly traded companies
- How to assess market potential
…then you need to download the article now.
Patrick Enright, will be chairing the successful Pitch & Partner program at this year’s World Orphan Drug Congress USA this coming April, where emerging orphan drug biotechs and potential partners and investors will meet to discuss licensing, partnering and investing opportunities. Make sure you’re there to join this interactive discussion! For more information, download the brochure.
See more at here.